Pediatric low-grade glioma is the most common brain tumor diagnosed in children, accounting for 30% to 50% of all central nervous systems tumors. In the case of most patients facing a recurrence, there is currently no established standard of care or approved treatment.
The company we are profiling today is Day One Biopharmaceuticals (DAWN), which is developing a drug for relapsed or progressive pediatric low-grade glioma.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.